Brought to you by 
AstraZeneca gets rights to AtheroGenics's AGI1067; terminated
03 Dec 2015
Executive Summary
AstraZeneca has licensed exclusive worldwide development and commercialization rights to AtheroGenics' (inflammatory disease therapeutics) AGI1067 for atherosclerosis. The oral compound blocks signaling pathways in endothelial cells that are involved in chronic cardiovascular inflammation and atherosclerosis.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Terminated
Deal Type
-
Alliance
- Co-Promotion
- Includes Contract
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
AstraZeneca gets rights to AtheroGenics's AGI1067; terminated
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice